Home / Market News / $ENLV
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

Enlivex Announces Positive Interim DSMB Safety Review for Phase IIb Knee Osteoarthritis Trial

Nov 19, 2026, 7:02 AM UTC · Primary ticker $ENLV

Enlivex announced that its independent Data and Safety Monitoring Board (DSMB) completed an interim safety review for its Phase IIb trial of Allocetra for knee osteoarthritis. The DSMB confirmed a consistent safety profile, allowing the trial to continue as planned, which is a positive step for the company's drug development program.

Enlivex announced that the DSMB for its Phase IIb trial of Allocetra for knee osteoarthritis completed an interim safety review. The board found the safety profile consistent with previous trials, recommending the continuation of patient enrollment. This is a positive development for Enlivex as it de-risks the trial from a safety perspective and allows the study to progress without interruption. For traders, this reduces immediate downside risk related to safety concerns and maintains the potential for future positive efficacy data, which would be a much larger catalyst. The short-term implication is a modest positive sentiment, while the long-term implication hinges on the eventual efficacy results of the ongoing trial.

$ENLV positive Trial continuation confirmed
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.